Navigation Links
Some patients with incurable tumors and BRCA mutations respond to new 2-drug combination
Date:4/7/2013

WASHINGTONA novel combination of two drugs has shown anti-cancer activity in patients who had incurable solid tumors and carried a germline mutation in their BRCA genes, Dana-Farber Cancer Institute researchers are reporting at the American Association for Cancer Research annual meeting in Washington, April 6-10.

The findings (abstract LB-202) will be released at a press conference on Sunday, April 7, 2 p.m. ET, and later at an oral presentation on Tuesday, April 9, 2 p.m. ET, in Room 153, in the Washington Convention Center.

The two oral drugs, sapacitabine and seliciclib, were given sequentially in a phase 1 clinical trial that is mainly enrolling patients whose tumors lack BRCA function because of an inherited mutation.

"We have seen several responses among these patients, as well as instances of prolonged stable disease lasting more than a year," said Geoffrey Shapiro, MD, PhD, director of Dana-Farber's Early Drug Development Center (EDDC). As a result, he said that a BRCA mutation may be a potential biomarker that identifies patients who are more likely to respond to the drug combination.

Sixteen patients enrolled in the trial carried an inherited BRCA mutation. Four of these patients had partial responses a 30 percent or greater shrinkage of tumor mass including one with pancreatic, two with breast, and one with ovarian cancer. Three patients were continuing to have a partial response at the time of presentation of the data, with the longest lasting more than 78 weeks. Two additional BRCA mutation carriers, with breast and ovarian cancer, experienced stable disease for 21 and 64 weeks, respectively. Of the remaining 22 patients enrolled in the trial, six experienced stable disease for 12 weeks or more.

Sapacitabine is toxic to cancer cells by causing damage to their DNA, which, if not repaired, causes the cells to self-destruct. The BRCA protein is essential for repair of the DNA damage caused by sapacitabine, so patients with mutations that inactivate BRCA may be more sensitive to the drug's activity.

The second drug, seliciclib, is an inhibitor of cyclin-dependent kinases (CDKs), enzymes that have multiple cellular functions, including a role in DNA repair, further augmenting the effects of sapacitabine. The patients in the trial received sapacitabine twice daily for seven days, followed by seliciclib twice daily for three days. Adverse events were mild to moderate in intensity, the study found.

Shapiro and colleagues are continuing to enroll BRCA mutation carriers in the trial, and hope to determine if the mutations may serve as a biomarker for response. He said that these drugs may prove to be an important treatment alternative for patients with BRCA-deficient cancers.


'/>"/>

Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. 2-step ovarian cancer immunotherapy made from patients own tumor shows promise
2. Liver transplantation for patients with genetic liver conditions has high survival rate
3. Penn Study finds virtual colonoscopy is used appropriately, may expand screening to more patients
4. Not all patients benefit equally from hip or knee replacement: Study finds
5. Cancer Patients May Be Unintended Victims of Budget Cuts
6. WINFertility Treatment Program Expands to Central/Southern Texas. Program Makes IVF Treatment More Affordable for Patients Without Infertility Insurance Coverage.
7. Medical patients arent bargain hunters
8. Advances in molecular testing offer new hope for lung cancer patients
9. ER Workers Often Fail to Ask Suicidal Patients About Access to Guns
10. Most Doctors Dont Help Lung Cancer Patients Quit Smoking: Survey
11. DrugRisks Stryker Recall Update: Company Warns Investors as Patients Alleging Injury Ask to Send Lawsuits to Federal Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... May 31, 2016 , ... Interest is on the rise ... and as an orthogonal tool for RNAi hit validation. A key reason may be ... RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed formats. , ...
(Date:5/31/2016)... ... May 31, 2016 , ... In a recent interview on The Greenburgh Report ... Rochelle, NY-based WVOX (1460 AM), leading medical insurance advocate Adria Goldman Gross ... “modern medical money maelstrom.” , During the interview with Mr. Feiner that aired ...
(Date:5/31/2016)... IL (PRWEB) , ... May 31, 2016 , ... ... multichannel marketing services firm and statement solutions provider, for the tenth ... in the May 2016 issue of Advertising Age, and SourceLink ranked eighteenth in ...
(Date:5/31/2016)... ... ... Super Powder, a supplement produced by Prox Formulas for providing protein ... to transform the nutritional supplement industry by providing a safe, natural approach to enhanced ... (BCAA), alkaline minerals, wheat grass, digestive enzymes, Omega 3’s, Vit D3, Vit A, B1, ...
(Date:5/30/2016)... ... May 30, 2016 , ... Zane Benefits, the leader ... an original infographic, " Health Benefits Reimbursement Compliance Timeline ." , The ... complies with various federal regulations and reforms. , Navigating the new health reforms ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... 2016 RnRMarketResearch.com adds "Asthma - ... analysis of Asthma therapy at various stages, therapeutics assessment ... administration (RoA) and molecule type, along with latest updates, ... key players involved in the therapeutic development for Asthma ... Complete report on H1 2016 pipeline review of ...
(Date:5/30/2016)... 2016 According to a ... Market by Type (Stability, Raw Materials, Method Validation, ... (Pharmaceutical Companies, Medical Device Companies) - Global Forecast ... healthy growth during the last decade and is ... between 2016 and 2021 to reach USD 4.13 ...
(Date:5/30/2016)... - DCGI grants limited approval to market Stempeucel® product for ... Stempeucel® becomes 5th off-the-shelf Stem cell product to be approved by ... Disease (also known as Thromboangiitis Obliterans) is a major unmet medical ... - Prevalence of Buerger,s Disease is estimated to be 1,000,000 in ... the European Community & USA ...
Breaking Medicine Technology: